Is Cronos Group Stock a Buy?
It's been an up-and-down year for companies across all sectors of the stock market. The volatility has been keenly felt by cannabis companies, which were severely wounded by retail closures, interruptions in supply chains, and general economic uncertainty due to the COVID-19 pandemic.
Cronos Group's (NASDAQ: CRON) viability as a buy-and-hold investment has long been in doubt. Strapped with debt and a hemorrhaging balance sheet, shares of the Canadian cannabinoid company have fallen by more than 53% from where the stock was trading just 12 months ago. Despite its financial troubles, the company is extremely popular with Robinhood investors, probably due to its cheap share price. On Sept. 16, the stock closed at just $5.40.
But a cheap share price is not always a signal of a great stock. Here's what you need to know before you hit the "buy" button on Cronos Group.
Source Fool.com
